• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ALX Oncology Appoints Allison Dillon as Chief Business Officer

    5/7/24 9:00:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALXO alert in real time by email

    SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the appointment of Allison Dillon, Ph.D., as Chief Business Officer ("CBO").

    "We are excited to welcome Allison to our leadership team in the midst of this promising growth period for our Company," said Jason Lettmann, Chief Executive Officer of ALX Oncology. "For over 15 years, Allison has worked to develop and deliver novel oncology products to patients with cancer. With multiple clinical study readouts over the next 12 months, Allison's deep oncology market expertise and impressive track record in executing portfolio, development, and commercial strategy will be vital in our endeavor to propel evorpacept to its full potential as a first-in-class, universal combination agent with anti-cancer antibodies, antibody-drug conjugates, and checkpoint inhibitors."

    "Evorpacept has immense potential to positively impact the lives of people with cancer," said Dr. Dillon, CBO of ALX Oncology. "With near-term clinical trial readouts and a strong balance sheet, ALX Oncology is well positioned for greater success. I am thrilled to begin working with this impressive team as we continue elevating our science and value through this exciting next chapter."

    Dr. Dillon joined ALX Oncology from Calithera Biosciences, where she most recently served as Senior Vice President of Commercial and Portfolio Strategy until 2023. During her time at Calithera, Dr. Dillon spearheaded commercial planning across a pipeline of hematology, solid tumors, and cystic fibrosis molecules. As Senior Vice President, Dr. Dillon also led corporate communications, including public and investor relations functions. Dr. Dillon helped oversee successful fundraising activities and acquisition of drugs such as mivavotinib and sapansertib from Takeda. Prior to joining Calithera in 2017, Dr. Dillon's expertise on pre- and post-launch commercialization strategy grew during her time at Genentech. Dr. Dillon drove the commercial launch plan for the initial launch of TECENTRIQ® (atezolizumab) in the US, and multiple subsequent launches, later serving as the Marketing Lead for GU indications. Additionally, she was the U.S. commercial representative on various Roche global business teams that informed investments. She served in marketing and sales roles for AVASTIN® (bevacizumab), TARCEVA® (erlotinib), ZELBORAF® (vemurafenib), and TECENTRIQ. Prior to Genentech, Dr. Dillon was a Senior Consultant at the management consulting firm Campbell Alliance, working across pharma and biotech clients. Prior to consulting, she was a Postdoctoral Fellow at the University of California San Francisco, Howard Hughes Medical Institute studying genetic pathways involved in medulloblastoma. Dr. Dillon holds a Ph.D. and M.S. in Neuroscience from Albert Einstein College of Medicine and a B.A. in Psychology from the University of Richmond.

    About ALX Oncology

    ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. ALX Oncology's lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. To date, evorpacept has been dosed in over 500 subjects and has demonstrated promising activity and favorable tolerability profile across a range of hematologic and solid malignancies in combination with various leading anti-cancer antibodies. ALX Oncology is currently focusing on combining evorpacept with anti-cancer antibodies, antibody-drug conjugates ("ADCs"), and PD-1/PD-L1 immune checkpoint inhibitors.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements regarding future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, plans and objects of management for future operations, as well as statements regarding industry trends. Such forward-looking statements are based on ALX Oncology's beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology's actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in ALX Oncology's filings with the Securities and Exchange Commission ("SEC"), including ALX Oncology's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents ALX Oncology files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.



    Investor and Media Contact:
    
    Caitlyn Doherty
    Manager, Investor Relations and Corporate Communications, ALX Oncology
    [email protected]
    (650) 466-7125

    Primary Logo

    Get the next $ALXO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALXO

    DatePrice TargetRatingAnalyst
    3/6/2025$2.00 → $3.00Hold → Buy
    Jefferies
    12/19/2024$12.00 → $2.00Buy → Hold
    Jefferies
    3/8/2024$10.00 → $14.00Buy → Hold
    Stifel
    12/8/2023$8.00 → $18.00Hold → Buy
    Jefferies
    3/1/2022$60.00 → $36.00Buy
    Stifel
    12/22/2021$65.00 → $25.00Buy → Hold
    Jefferies
    9/30/2021$106.00Buy
    Stifel
    More analyst ratings

    $ALXO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Lettmann Jason bought $99,352 worth of shares (92,233 units at $1.08), increasing direct ownership by 43% to 305,121 units (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    9/18/25 4:23:19 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Shantharam Harish bought $58,402 worth of shares (75,000 units at $0.78) (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    8/20/25 4:02:05 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hemrajani Rekha bought $46,404 worth of shares (30,000 units at $1.55), increasing direct ownership by 1,000% to 33,000 units (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    12/4/24 4:17:28 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Klencke Barbara

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    9/19/25 4:01:03 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Lettmann Jason bought $99,352 worth of shares (92,233 units at $1.08), increasing direct ownership by 43% to 305,121 units (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    9/18/25 4:23:19 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Shantharam Harish bought $58,402 worth of shares (75,000 units at $0.78) (SEC Form 4)

    4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

    8/20/25 4:02:05 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    SEC Filings

    View All

    ALX Oncology Holdings Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - ALX ONCOLOGY HOLDINGS INC (0001810182) (Filer)

    9/12/25 8:32:27 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by ALX Oncology Holdings Inc.

    SCHEDULE 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

    8/14/25 4:17:11 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by ALX Oncology Holdings Inc.

    10-Q - ALX ONCOLOGY HOLDINGS INC (0001810182) (Filer)

    8/12/25 4:07:50 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

    Company will share data demonstrating CD47 overexpression as key predictive biomarker for response with the Company's lead candidate, evorpacept, in HER2+ gastric cancer SOUTH SAN FRANCISCO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced updated data from its Phase 2 ASPEN-06 (NCT05002127) trial will be presented during a poster session at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting taking place November 5–9, 2025, in National Harbor, Maryland. The P

    10/3/25 9:05:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

    Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company's Board of Directors and will step down from the Board to join ALX as Interim Chief Medical Officer Alan Sandler, M.D. resigns as Chief Medical Officer and will return to his position serving on the Company's Board of Directors SOUTH SAN FRANCISCO, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced the appointment of Dr. Kl

    9/12/25 8:30:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology to Participate in Upcoming Investor Conferences in September

    SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in both the Cantor Global Healthcare Conference 2025 and H.C. Wainwright 27th Annual Global Investment Conference in New York. The details of the meetings are as follows: Cantor Global Healthcare Conference Format: Fireside Chat and One-on-one MeetingsDate: Wednesday, September 3, 2025Location: New York, NYTime of Fireside Chat Presentation: 9:45 AM ETWebcast

    8/29/25 12:00:00 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ALX Oncology upgraded by Jefferies with a new price target

    Jefferies upgraded ALX Oncology from Hold to Buy and set a new price target of $3.00 from $2.00 previously

    3/6/25 7:17:16 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology downgraded by Jefferies with a new price target

    Jefferies downgraded ALX Oncology from Buy to Hold and set a new price target of $2.00 from $12.00 previously

    12/19/24 7:28:17 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology downgraded by Stifel with a new price target

    Stifel downgraded ALX Oncology from Buy to Hold and set a new price target of $14.00 from $10.00 previously

    3/8/24 7:21:35 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    Leadership Updates

    Live Leadership Updates

    View All

    ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

    Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company's Board of Directors and will step down from the Board to join ALX as Interim Chief Medical Officer Alan Sandler, M.D. resigns as Chief Medical Officer and will return to his position serving on the Company's Board of Directors SOUTH SAN FRANCISCO, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced the appointment of Dr. Kl

    9/12/25 8:30:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors

    Mr. Shantharam is a proven biotech industry executive with over two decades of senior leadership experience in finance, commercial and corporate operationsDr. Klencke is a seasoned clinical leader in oncology drug development with more than 20 years of industry experienceDr. Takimoto brings a distinguished track record in oncology and drug development with 17 years of industry experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced the appointmen

    1/22/25 8:00:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

    SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients' lives, announced today the appointment of Alan Sandler, M.D., as Chief Medical Officer. "Dr. Sandler's breadth of experience and demonstrated leadership capabilities across oncology and drug development, as well as his in-depth knowledge of ALX Oncology while he was a member of our Board, will be instrumental in helping us achieve our near- and longer-term objectives," said Jason Lettmann, Chief Executive Officer at

    11/14/24 8:00:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    Financials

    Live finance-specific insights

    View All

    ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    – Data from ASPEN-06 trial highlights CD47 expression as a key predictive biomarker of greater response to evorpacept in HER2+ Gastric Cancer; updated data to be presented at a medical conference in Q4 2025 – Phase 2 ASPEN-Breast evorpacept trial design updated to enable CD47 and HER2 biomarker-driven strategy in a single-arm study; anticipated interim data readout in Q3 2026 – ALX2004 Phase 1 clinical trial remains on track to enroll first patient in August – Focus on driving ASPEN-Breast and ALX2004 data milestones within the cash runway, now extended into Q1 2027 – Appoints Daniel Curran, M.D. to the Board of Directors – Company to host webcast Tuesday, August 12 at 1:30 p.m. PT/4:30

    8/12/25 4:05:00 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025

    SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its second quarter 2025 financial results and a business update on Tuesday, August 12th, 2025, after market close. The company will be hosting a teleconference in conjunction with its financial results press release. Second Quarter 2025 Webcast Information Date & Time: Tuesday, August 12, 2025 at 1:30pm PT / 4:30pm ET Webcast Access: https://viavid.webcasts.com/starthere.jsp?ei=1729703&tp

    8/5/25 8:00:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

    SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its first quarter 2025 financial results on Thursday, May 8th, 2025, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About ALX OncologyALX Oncology (NASDAQ:ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives. ALX Oncology's lea

    5/2/25 8:00:00 AM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALXO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

    SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

    11/14/24 7:22:54 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

    SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

    11/14/24 6:58:27 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

    SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

    11/14/24 3:02:41 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care